Strata Skin SciencesFRA:E2O 38 PB Ratio is 8.91 as of Jul. 11, 2026, which is 427% above its 10-year median of 1.69. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €59.29. The stock has 5 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Strata Skin Sciences ranks worse than 127226.34% on this metric.
Strata Skin Sciences Inc stock PB Ratio (=0.26) is close to 5-year low of 0.24.
The historical rank and industry rank for Strata Skin Sciences's PB Ratio or its related term are showing as below:
FRA:E2O'
s PB Ratio Range Over the Past 10 Years
Min: 0.12 Med: 1.69 Max: 32.16
Current: 0.26
During the past 13 years, Strata Skin Sciences's highest PB Ratio was 32.16. The lowest was 0.12. And the median was 1.69.
FRA:E2O's PB Ratio is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 2.06
vs FRA:E2O: 0.26
During the past 12 months, Strata Skin Sciences's average Book Value Per Share Growth Rate was -58.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -57.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -43.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -36.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Strata Skin Sciences was 62.50% per year. The lowest was -57.20% per year. And the median was -22.60% per year.
Back to Basics: PB Ratio
Strata Skin Sciences (FRA:E2O) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Strata Skin Sciences PB Ratio Related Terms
Strata Skin Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Strata Skin Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Strata Skin Sciences (FRA:E2O) has a PB Ratio of 8.91 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Strata Skin Sciences and its competitors. This is 427% above median its historical median of 1.69. Over the past decade, Strata Skin Sciences' PB Ratio has ranged from 0.12 to 32.16. According to the industry distribution chart, Strata Skin Sciences ranks #999999 out of 786 companies in the Medical Devices & Instruments industry.
Is Strata Skin Sciences' PB Ratio too high?
Strata Skin Sciences' current PB Ratio of 8.91 is 427% above median its 10-year median of 1.69. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 32.16. The Medical Devices & Instruments industry median PB Ratio is 2.06. Strata Skin Sciences' value of 8.91 is 332.5% above this industry median. Based on the distribution chart, Strata Skin Sciences ranks #999999 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' PB Ratio compare to ODYY and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #999999 out of 786 companies for PB Ratio. This places Strata Skin Sciences in the lower half of its industry. The industry median PB Ratio is 2.06. Strata Skin Sciences' value of 8.91 is 332.5% above this benchmark. Historically, Strata Skin Sciences' own PB Ratio has ranged from 0.12 to 32.16 over the past decade. While the company's 10-year median is 1.69 vs. the industry median of 2.06, Strata Skin Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current PB Ratio of 8.91 is 332.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current PB Ratio is 8.91, which is 427% above median its own 10-year median of 1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current PB Ratio of 8.91. The stock's GF Value™ is €59.29, compared to a current price of €3.76 — trading 93.7% below its estimated fair value. The current PB Ratio is 8.91, which is 427% above median its 10-year median of 1.69 and 332.5% above the Medical Devices & Instruments industry median of 2.06. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current PB Ratio is 8.91 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 93.7% below its estimated GF Value™ of €59.29.
Key valuation signals for FRA:E2O:
PB Ratio: 8.91 (427% above median its 10-year median of 1.69)
GF Value™: €59.29 vs. price of €3.76 (93.7% below fair value)
Industry Position: 332.5% above the Medical Devices & Instruments median (#999999 of 786)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
